Clinical trials: FLU
Virus Diseases
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to areas of inflammation.
- Trial name
- NCT02927431
- Testing
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Oseltamivir 75 mg
- Where
- 8 sites in United States, Romania and 2 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Influenza Vaccination
The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination
The purpose of this study is to evaluate whether message design of educational materials increases vaccination rates among participants.
- Trial name
- NCT01009645
- Testing
- Fact Only Education Message, Fact and Myth Educational Message, Fact, Myth, Why Educational Message
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Northwestern University
Influenza
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously vaccinated in Trial V118_05.
- Trial name
- NCT02583256
- Testing
- Adjuvanted QIV (aQIV), Non-adjuvanted QIV
- Where
- 17 sites in Finland, Philippines and 1 more
- Volunteers
- 1,601 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.
The purpose of this study is to collect safety information on the use of Fluarix Tetra according to the approved PI, in Korea, over a period of 6 years from children greater than or equal to (≥)3 years of age and adults, and over…
- Trial name
- NCT02663102
- Testing
- Data collection
- Where
- 21 sites in South Korea
- Volunteers
- 1,388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immune Deficiency, Metabolic Syndrome
Impact of Metabolic Syndrome on Flu Vaccine Efficacy
Metabolic syndrome (MetS) is a cluster of metabolic conditions associated with obesity that predispose individuals to coronary heart diseases and diabetes but obesity has been shown to increase the risks of other diseases like…
- Trial name
- NCT02653495
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Influenza
Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old
This study will evaluate the immunogenicity and the safety of PrepandrixTM in Korean subjects. A second group of subjects will receive FluarixTM vaccine as control.
- Trial name
- NCT01730378
- Testing
- Prepandrix™, Fluarix™
- Where
- 4 sites in South Korea
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine
The purpose of the study is to determine the amount of live virus that can be recovered from the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to describe the immune response to vaccination.
- Trial name
- NCT01023776
- Testing
- A/California/07/09 live monovalent H1N1 vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Human Influenza
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years and the antibody response to each influenza…
- Trial name
- NCT01885117
- Testing
- TIVf
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.
- Trial name
- NCT03883113
- Testing
- MVA-NP+M1, Saline, H3N2 (A/Belgium/2417/2015)
- Where
- Belgium
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Influenza
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
Background: Adjuvants are substances included in vaccines that stimulate the immune system and increase the body's response to the vaccine. The AS03 adjuvant is used in seasonal flu vaccines in Europe.
- Trial name
- NCT01578317
- Testing
- H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03022435
- Testing
- TIV, High-Dose TIV, LAIV
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza, Human
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza
This study will be divided into two substudies - Substudy A (SSA) and Substudy B (SSB) Substudy A This is a Phase 1 randomized substudy to evaluate the safety and immunogenicity of monovalent influenza modRNA vaccine (mIRV) and…
- Trial name
- NCT05052697
- Testing
- mIRV, bIRV AB, qIRV
- Where
- 100 sites in United States
- Volunteers
- 1,158 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly
The purpose of the present study is to assess the immunogenicity, safety and reactogenicity of a two-dose schedule with vaccine GSK2340272A when co-administered with GSK Biologicals' Fluarix™ vaccine either at the time of first…
- Trial name
- NCT00968890
- Testing
- Pandemrix (Influenza vaccine GSK2340272A), Fluarix™
- Where
- 2 sites in Sweden
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of Quadrivalent Influenza Vaccine Among Children
The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain (B1), and the investigational TIV containing the…
- Trial name
- NCT01240746
- Testing
- Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative, Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative, Quadrivalent Influenza Vaccine, No Preservative
- Where
- 67 sites in United States
- Volunteers
- 4,363 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy
Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route
Background: It is well established that live attenuated organisms can be highly effective vaccines, immune responses elicited can often be of greater magnitude and of longer duration than those produced by non-living antigens and…
- Trial name
- NCT01488188
- Testing
- Influenza vaccine
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Acellular Pertussis, Diphtheria
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00385255
- Testing
- Fluarix®, Boostrix®
- Where
- 12 sites in United States
- Volunteers
- 1,726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.
- Trial name
- NCT00964158
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Influenza
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of cell-derived, trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years and the antibody response to each…
- Trial name
- NCT01880697
- Testing
- TIVc
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pregnancy
PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging
In this study, the investigators will prospectively assess fever rates and other adverse events in pregnant women after administration of inactivated influenza vaccine (IIV) using text messaging.
- Trial name
- NCT01974050
- Testing
- Text message surveillance
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- Columbia University
Influenza A H1N1
Study of SAB-176 in Healthy Adult Participants
Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo.
- Trial name
- NCT04850898
- Testing
- SAB-176
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.